These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 25295235)
1. A quantitative and qualitative evaluation of the British Columbia Take Home Naloxone program. Banjo O; Tzemis D; Al-Qutub D; Amlani A; Kesselring S; Buxton JA CMAJ Open; 2014 Jul; 2(3):E153-61. PubMed ID: 25295235 [TBL] [Abstract][Full Text] [Related]
2. Qualitative assessment of take-home naloxone program participant and law enforcement interactions in British Columbia. Deonarine A; Amlani A; Ambrose G; Buxton JA Harm Reduct J; 2016 May; 13(1):17. PubMed ID: 27206486 [TBL] [Abstract][Full Text] [Related]
3. Lessons learned from ramping up a Canadian Take Home Naloxone programme during a public health emergency: a mixed-methods study. Young S; Williams S; Otterstatter M; Lee J; Buxton J BMJ Open; 2019 Oct; 9(10):e030046. PubMed ID: 31662368 [TBL] [Abstract][Full Text] [Related]
4. Correlates of seeking emergency medical help in the event of an overdose in British Columbia, Canada: Findings from the Take Home Naloxone program. Karamouzian M; Kuo M; Crabtree A; Buxton JA Int J Drug Policy; 2019 Sep; 71():157-163. PubMed ID: 30691944 [TBL] [Abstract][Full Text] [Related]
5. Factors associated with take-home naloxone kit usage in British Columbia: an analysis of administrative data. Lei V; Ferguson M; Geiger R; Williams S; Liu L; Buxton JA Subst Abuse Treat Prev Policy; 2022 Mar; 17(1):25. PubMed ID: 35361228 [TBL] [Abstract][Full Text] [Related]
6. The implementation and role of a staff naloxone program for non-profit community-based sites in British Columbia: A descriptive study. Williams S; King T; Papamihali K; Buxton JA PLoS One; 2021; 16(5):e0251112. PubMed ID: 33983996 [TBL] [Abstract][Full Text] [Related]
7. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study. Irvine MA; Buxton JA; Otterstatter M; Balshaw R; Gustafson R; Tyndall M; Kendall P; Kerr T; Gilbert M; Coombs D Lancet Public Health; 2018 May; 3(5):e218-e225. PubMed ID: 29678561 [TBL] [Abstract][Full Text] [Related]
8. Adverse events related to bystander naloxone administration in cases of suspected opioid overdose in British Columbia: An observational study. Moustaqim-Barrette A; Papamihali K; Williams S; Ferguson M; Moe J; Purssell R; Buxton JA PLoS One; 2021; 16(10):e0259126. PubMed ID: 34714854 [TBL] [Abstract][Full Text] [Related]
9. Awareness, Possession, and Use of Take-Home Naloxone Among Illicit Drug Users, Vancouver, British Columbia, 2014-2015. Nolan S; Buxton J; Dobrer S; Dong H; Hayashi K; Milloy MJ; Kerr T; Montaner J; Wood E Public Health Rep; 2017; 132(5):563-569. PubMed ID: 28750193 [TBL] [Abstract][Full Text] [Related]
10. Sweden's first Take-Home Naloxone program: participant characteristics, dose endpoints and predictors for overdose reversals. Holmén E; Warnqvist A; Kåberg M Subst Abuse Treat Prev Policy; 2023 Apr; 18(1):24. PubMed ID: 37087485 [TBL] [Abstract][Full Text] [Related]
11. Findings and lessons learnt from implementing Australia's first health service based take-home naloxone program. Chronister KJ; Lintzeris N; Jackson A; Ivan M; Dietze PM; Lenton S; Kearley J; van Beek I Drug Alcohol Rev; 2018 May; 37(4):464-471. PubMed ID: 27071354 [TBL] [Abstract][Full Text] [Related]
12. Naloxone and the Inner City Youth Experience (NICYE): a community-based participatory research study examining young people's perceptions of the BC take home naloxone program. Mitchell K; Durante SE; Pellatt K; Richardson CG; Mathias S; Buxton JA Harm Reduct J; 2017 Jun; 14(1):34. PubMed ID: 28592287 [TBL] [Abstract][Full Text] [Related]
13. Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives. Lintzeris N; Monds LA; Bravo M; Read P; Harrod ME; Gilliver R; Wood W; Nielsen S; Dietze PM; Lenton S; Shanahan M; Jauncey M; Jefferies M; Hazelwood S; Dunlop AJ; Greenaway M; Haber P; Ezard N; Malcom A Drug Alcohol Rev; 2020 Jan; 39(1):55-65. PubMed ID: 31774221 [TBL] [Abstract][Full Text] [Related]
14. Association of Take-Home Naloxone and Opioid Overdose Reversals Performed by Patients in an Opioid Treatment Program. Katzman JG; Takeda MY; Greenberg N; Moya Balasch M; Alchbli A; Katzman WG; Salvador JG; Bhatt SR JAMA Netw Open; 2020 Feb; 3(2):e200117. PubMed ID: 32101312 [TBL] [Abstract][Full Text] [Related]
15. Process evaluation of the Prevent Overdose in Toronto (POINT) program. Leece P; Gassanov M; Hopkins S; Marshall C; Millson P; Shahin R Can J Public Health; 2016 Oct; 107(3):e224-e230. PubMed ID: 27763835 [TBL] [Abstract][Full Text] [Related]
16. An evaluation of Take Home Naloxone program implementation in British Columbian correctional facilities. Pearce LA; Mathany L; Rothon D; Kuo M; Buxton JA Int J Prison Health; 2019 Mar; 15(1):46-57. PubMed ID: 30827160 [TBL] [Abstract][Full Text] [Related]
17. Intention to seek emergency medical services during community overdose events in British Columbia, Canada: a cross-sectional survey. Kievit B; Xavier JC; Ferguson M; Palis H; Moallef S; Slaunwhite A; Gillis T; Virk R; Buxton JA Subst Abuse Treat Prev Policy; 2022 Jul; 17(1):56. PubMed ID: 35883186 [TBL] [Abstract][Full Text] [Related]
18. Development and implementation of an opioid overdose prevention and response program in Toronto, Ontario. Leece PN; Hopkins S; Marshall C; Orkin A; Gassanov MA; Shahin RM Can J Public Health; 2013 Apr; 104(3):e200-4. PubMed ID: 23823882 [TBL] [Abstract][Full Text] [Related]
19. Addressing Intersecting Housing and Overdose Crises in Vancouver, Canada: Opportunities and Challenges from a Tenant-Led Overdose Response Intervention in Single Room Occupancy Hotels. Bardwell G; Fleming T; Collins AB; Boyd J; McNeil R J Urban Health; 2019 Feb; 96(1):12-20. PubMed ID: 30073598 [TBL] [Abstract][Full Text] [Related]
20. Awareness and knowledge of the Good Samaritan Drug Overdose Act among people at risk of witnessing an overdose in British Columbia, Canada: a multi-methods cross sectional study. Ackermann E; Kievit B; Xavier J; Barbic S; Ferguson M; Greer A; Loyal J; Mamdani Z; Palis H; Pauly B; Slaunwhite A; Buxton JA Subst Abuse Treat Prev Policy; 2022 May; 17(1):42. PubMed ID: 35614474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]